Vaccination Against Influenza in Autoimmune Diseases (MAIVAX)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01065285 |
Recruitment Status :
Completed
First Posted : February 9, 2010
Last Update Posted : January 6, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Autoimmune Diseases | Biological: Evaluation of vaccines against flu | Phase 4 |
This prospective study concentrates on patients with vasculitis, systemic sclerosis, Sjögren's syndrome, systemic lupus erythematosus and other connective tissue diseases.
Patients responding to the inclusion criteria, will receive vaccine against seasonal influenza then, 3 weeks later, vaccine against H1N1 influenza. According to the results of ongoing trials a second injection of H1N1 vaccine has been scheduled 3 weeks later. At each consultation a blood sample will be taken to evaluate immunogenicity of vaccination. Two additional consultations have been scheduled: one month after the last vaccine administration and at 6 month, in order to evaluate the occurrence of late side effects.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 234 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Evaluation of Vaccination Against Influenza (Seasonal and H1N1) in Patients Presenting Systemic or Autoimmune Diseases Treated or Not With Steroids, and/or Immunosuppressant, and/or Biotherapy: an Open, Prospective Trial (MAIVAX) |
Study Start Date : | October 2009 |
Actual Primary Completion Date : | July 2011 |
Actual Study Completion Date : | February 2012 |

Arm | Intervention/treatment |
---|---|
Experimental: Evaluation of vaccines against flu
Evaluation of vaccines against flu
|
Biological: Evaluation of vaccines against flu
evaluate efficacy and tolerance
Other Name: Evaluation of vaccines against flu in auto-imune diseases |
- Protection against H1N1 influenza, defined by antibody level of 1/40, measured by hemagglutination, 3 weeks after the first injection and after the second injection [ Time Frame: 3 weeks ]Mesure of antibody level of 1/40, measured by hemagglutination, 3 weeks after the first injection and after the second injection
- Antibody levels against H1N1 in the different groups of patients, defined according diseases and their treatment (comparison of patients treated by immunosuppressants or not treated) [ Time Frame: 3 weeks ]Antibody levels against H1N1 in the different groups of patients, defined according diseases and their treatment
- Number of side effects related to vaccination [ Time Frame: 3 weeks ]
- Number of local side effects related to vaccination (erythema and/or pain at injection site) [ Time Frame: 3 weeks ]
- Number of patients who will develop influenza despite vaccination [ Time Frame: 3 weeks ]
- Number of patients who had antibodies against H1N1 before vaccination [ Time Frame: 3 weeks ]
- Number of hospitalisations and deaths related to influenza [ Time Frame: 3 weeks ]
- Number of flares of the autoimmune diseases that could be related to vaccination [ Time Frame: 3 weeks ]
- Determine if the induction of LT-CD4 to J21-28 anti-jams is correlated to the concentrations of antibody anti-vaccines measured in 6 months [ Time Frame: 18 months ]
- Determine if the basal concentrations of LT-CD4 anti-jam to J21-J28 are correlated to the concentrations of antibody anti-vaccines measured in 6 months [ Time Frame: 18 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adult patients presenting autoimmune and systemic diseases,
- treating or not with steroids, and/or immunosuppressants and/or biotherapies, especially vasculitis, scleroderma, Sjogren's syndrome and systemic lupus (main groups)
Exclusion Criteria:
- Absence of informed consent
- Disease which did not responded to the above criteria
- Active infection at time of vaccination
- HIV infection
- History of Guillain-Barre syndrome
- Allergy to one component of the vaccine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01065285
France | |
Hopital Cochin | |
Paris, France, 75014 |
Principal Investigator: | Loïc GUILLEVIN, MD PhD | Assistance Publique - Hôpitaux de Paris |
Publications of Results:
Responsible Party: | Assistance Publique - Hôpitaux de Paris |
ClinicalTrials.gov Identifier: | NCT01065285 History of Changes |
Other Study ID Numbers: |
P 090901 |
First Posted: | February 9, 2010 Key Record Dates |
Last Update Posted: | January 6, 2016 |
Last Verified: | July 2012 |
Influenza autoimmune diseases vaccination H1N1 |
Influenza, Human Autoimmune Diseases Orthomyxoviridae Infections RNA Virus Infections Virus Diseases Respiratory Tract Infections |
Respiratory Tract Diseases Immune System Diseases Vaccines Immunologic Factors Physiological Effects of Drugs |